Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
The current price of 10V.MU is €12.60 EUR — it has increased by +0.2% in the past 24 hours. Watch Immunic stock price performance more closely on the chart.
What is Immunic stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Immunic stocks are traded under the ticker 10V.MU.
What is Immunic market cap?▼
Today Immunic has the market capitalization of 171.56M
When is the next Immunic earnings date?▼
Immunic is going to release the next earnings report on August 06, 2026.
What were Immunic earnings last quarter?▼
10V.MU earnings for the last quarter are -0.92 EUR per share, whereas the estimation was -0.59 EUR resulting in a -57.09% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Immunic revenue for the last year?▼
Immunic revenue for the last year amounts to 0 EUR.
What is Immunic net income for the last year?▼
10V.MU net income for the last year is -84.54M EUR.
In which sector is Immunic located?▼
Immunic operates in the Other sector.
When did Immunic complete a stock split?▼
The last stock split for Immunic was on April 27, 2026 with a ratio of 1:10.